Phaseline

Companies › Moleculin Biotech

Moleculin Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Aug 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
L-Annamycin for Injection
Topoisomerase II inhibitor
–Phase 2Acute Myeloid Leukaemia (AML)Aug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06788756L-Annamycin for InjectionPhase 2Acute Myeloid Leukaemia (AML)OncologyAug 2029

From the company's SEC filings

Cash of $7m on 2026-06-30; operating cash outflow about $26m a year; runway about 3 months at that burn, to Oct 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Processa Pharmaceuticals Dogwood Therapeutics Atossa Therapeutics Curis CNS Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.